Showing 5091-5100 of 5252 results for "".
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and B
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- Merz CEO Focused on Advancing the Companyhttps://practicaldermatology.com/news/20120515-merz_ceo_focused_on_advancing_the_company/2459801/William “Bill” Humphries, newly appointed CEO of Merz, Inc., has been setting the record straight. For example, addressing a recent injunction that bars the marketing of Xeomin for aesthetic indications, he insists, “the impact of the injunction isn
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- Novartis Acquires Fougera Pharma for $1.5 Billionhttps://practicaldermatology.com/news/20120504-novartis_acquires_fougera_pharma_for_15_billion/2459809/With it's $1.5 billion acquisition of US-based Fougera Pharmaceuticals, Novartis will be the biggest maker of dermatologic generics in the country. The Fougera products will add to those of Novartis's existing generics unit Sandoz.
- PhotoMedex Completes Sale of Common Stock for $40 Millionhttps://practicaldermatology.com/news/20120430-photomedex_completes_sale_of_common_stock_for_40_million/2459812/PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. The company closed concurrent registered offerin
- Lasers May Treat Burn Scars of Military, Civilianshttps://practicaldermatology.com/news/20120420-lasers_may_treat_burn_scars_of_military_civilians/2459817/Fractional laser procedures may offer a treatment option for the estimated 1 million American who survive serious burn injuries each year, according to experts presenting at the ASLMS Annual Meeting in Kissimmee, FL. According to Jill Waibel, MD, credited with performing one of (or pe
- Study Shows No Association Between NSAIDs and BCChttps://practicaldermatology.com/news/20120418-study_shows_no_association_between_nsaids_and_bcc/2459821/New data question an association between NSAID use and development of BCC, showing that NSAID use was not associated with subsequent incidence of BCC (HR = 1.04, 95% CI: 0.92–1.16) after adjusting for age, sex and estimated lifetime summer sun exposure among a cohort of 58,213 Caucasian Radiologic T
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos